**DEPARTMENT OF HEALTH AND HUMAN SERVICES**
**National Institutes of Health**
**National Cancer Institute**
**Bethesda, Maryland**

**AGENDA**

**66th Meeting**
**of the**
**NCI Council of Research Advocates (NCRA)**

**October 21, 2014**

**Tuesday, October 21 - OPEN**
**Conference Room 6, C Wing, Building 31**

**9:00 a.m. – 9:20 a.m.**

I. CALL TO ORDER AND OPENING REMARKS — Mr. Wallace, Ms. Landy

II. FUTURE MEETING DATES

**NCRA Confirmed:**

| | |
|---|---|
| February 5, 2015 | Thursday |
| June 22, 2015 | Monday |
| October 19, 2015 | Monday |

**9:20 a.m. - 9:50 a.m.**

III. THE ROLE OF ADOPTIVE T-CELL THERAPY — Dr. Rosenberg

**9:50 a.m. - 10:20 a.m.**

IV. IMMUNOTHERAPIES IN CHILDHOOD CANCER — Dr. Mackall

**10:20 a.m. - 10:50 a.m.**

V. THERAPEUTIC CANCER VACCINES — Dr. Schlom

**10:50 a.m. - 11:20 a.m.**

VI. CANCER IMMUNOPREVENTION EFFORTS — Dr. Schiller

**11:20 a.m. – 11:30 a.m.**

COFFEE BREAK

**11:30 a.m. – 12:00 p.m.**

| | | |
|---|---|---|
| VII. | NCI DIRECTOR'S UPDATE | Dr. Varmus |

**12:00 p.m. - 1:00 p.m.**

LUNCH

**1:00 p.m. – 1:30 p.m.**

| | | |
|---|---|---|
| VIII. | REGULATORY ADVANCES IN CANCER IMMUNOTHERAPIES | Dr. Bross |

**1:30 p.m. – 2:00 p.m.**

| | | |
|---|---|---|
| IX. | PARTNERING WITH THE PRIVATE SECTOR TO ADVANCE CANCER IMMUNOTHERAPIES | Ms. Selig |

**2:00 p.m. – 2:40 p.m.**

X. FACILITATED DISCUSSION: HOW ADVOCATES CAN ADVANCE CANCER IMMUNOTHERAPY RESEARCH

**2:40 p.m. – 3:10 p.m.**

| | | |
|---|---|---|
| XI. | WORKING GROUP UPDATES | Ms. Harris<br>Mr. Retzlaff<br>Mr. Wallace |

**3:10 p.m. – 3:30 p.m.**

XII. OPEN DISCUSSION

**3:30 p.m.**

XIII. ADJOURNMENT

## SPEAKERS

Peter Bross, M.D.
Medical Review Officer
Office of Cellular, Tissue, and Gene Therapies
Center for Biologics Evaluation and Research
Food and Drug Administration
Silver Spring, MD

Joya Delgado Harris, M.P.H.
Director
Office of Research Integration
American Cancer Society
Atlanta, GA

Kelley Landy, M.P.A.
Acting Director
Office of Advocacy Relations
Office of the Director
National Cancer Institute
National Institutes of Health
Bethesda, MD

Crystal Mackall, M.D.
Chief, Pediatric Oncology Branch
Head, Immunology Section
Center for Cancer Research
National Cancer Institute
National Institutes of Health
Bethesda, MD

Jon Retzlaff, M.P.A., M.B.A.
Managing Director
Science Policy and Government Affairs
American Association for Cancer Research
Washington, DC

Steven A. Rosenberg, M.D., Ph.D.
Chief, Surgery Branch
Head, Tumor Immunology Section
Center for Cancer Research
National Cancer Institute
National Institutes of Health
Bethesda, MD

John T. Schiller, Ph.D.
Deputy Chief, Laboratory of Cellular Oncology
Head, Neoplastic Disease Section
Center for Cancer Research
National Cancer Institute
National Institutes of Health
Bethesda, MD

Jeffrey Schlom, Ph.D.
Chief, Laboratory of Tumor Immunology and Biology
Head, Immunotherapeutics Group
Center for Cancer Research
National Cancer Institute
National Institutes of Health
Bethesda, MD

Wendy K.D. Selig
President and Chief Executive Officer
Melanoma Research Alliance (MRA)
Washington, DC

Harold E. Varmus, M.D.
Director
National Cancer Institute
National Institutes of Health
Bethesda, MD

Max Wallace, J.D.
Chief Executive Officer
Accelerate Brain Cancer Cure
Washington, DC